GILDGilead Sciences, Inc.
Earnings Recap
• Reported GAAP EPS of $1.76 up 23.08% YoY • Reported revenue of $7.92B up 4.70% YoY • Gilead expects full year 2026 product sales between $29.6B and $30B, with diluted EPS projected to be in the range of $6.75 to $7.15, and non-GAAP diluted EPS between $8.45 and $8.85.
Bullish
Gilead achieved strong fourth quarter revenue growth, driven by robust HIV and Liver Disease product sales. Positive Phase 3 results for BIC/LEN and a Yescarta label update highlight pipeline progress, while Gilead also generated significant operating cash flow.
Bearish
Gilead faced decreased sales for Veklury and Cell Therapy due to competitive headwinds and lower COVID-19 hospitalizations. Clinical trial setbacks for Trodelvy and domvanalimab, plus higher acquired IPR&D expenses, impacted Gilead's performance.